Illumina and Trivitron Partner to Accelerate Disease Detection and Diagnosis for Patients in India
Partnership will expand use of next-generation sequencing (NGS) to help diagnose patients quickly and more accurately.
Originally published on Trivitron Healthcare
NEW DELHI, March 15, 2022 /3BL Media/ - Illumina Singapore, subsidiary of Illumina Inc (NASDAQ: ILMN) and Trivitron Healthcare, one of India's largest medical technology companies, have entered into a strategic partnership to develop and expand the use of next-generation sequencing (NGS)-based in-vitro diagnostic tests (IVD) in India.
Over the next four years, Illumina and Trivitron intends to develop and distribute a suite of standardized, commercial IVD assays to deliver an effective and non-invasive way of diagnosing cancers, determining infectious pathogens, and identifying prenatal diseases. The assays will be cost-effective, easy to use, and have high throughput capabilities.
“Illumina believes in democratizing access to sequencing. There is a vital need to make genomic technology and precision medicine available to all.” said Gretchen Weightman, Head of Global Commercial Strategy and General Manager of Asia Pacific and Japan at Illumina.
Ms Weightman added “Our collaboration with Trivitron will increase access for patients in India to genomics and expand on Illumina's solid history and broad portfolio of partnerships with industry leaders, with the united goal of advancing diagnostics and precision medicine.”
“We are pleased to announce our partnership with Illumina as we will be able to develop creative, adaptable, and scalable solutions to address the demands of Indian patients as a result of our collaboration.” said Dr. GSK Velu, Chairman & Managing Director, Trivitron Healthcare.
“With this partnership, Trivitron will build improved NGS-based diagnostic tests across a variety of disease categories on Illumina’s sequencing technology as part of this collaboration. The improved and locally-designed diagnostic tests will be manufactured and marketed by Trivitron following regulatory approvals.” he said.
In numerous neurological and rare disorders, where clinical characteristics can be confusing, NGS-based approaches have demonstrated considerable increases in disease detection rates over other approaches. Similarly, tailored NGS panels have allowed for the rapid, non-invasive, and cost-effective diagnosis and prognosis of a variety of malignancies, as well as the detection of infectious pathogens and the identification of a variety of prenatal disorders.
In addition to this partnership, in August 2020, Illumina collaborated with the Institute of Genomics & Integrative Biology in New Delhi to evaluate COVIDSeq and increase availability of frontline testing.
About Trivitron
Since 1997, the journey of Trivitron Healthcare as a medical technology company providing affordable healthcare solutions weaves a fascinating thread of inspiration to many healthcare providers. Trivitron markets its products to hospitals, individual healthcare providers, independent clinics and laboratories, extended care facilities , renal care centres and all other roofs providing healthcare solutions. As a pioneer in the field, Trivitron constantly pursues technological innovations to offer superior clinical benefits at a lower cost. At Trivitron, quality healthcare is considered as a fundamental right and the vision is to make it available for the people of all classes.
Having a solid expertise in research and development, Trivitron manufactures and distributes exceptional medical technology products to 180 countries. A family of 1500 employees housed in 25 offices and the support of 1200 channel partners prepares the organization for the unexpected challenges and aligns the daily activities in line with its vision. With 13 USFDA, CE certified manufacturing facilities, supported by several R&D tie-ups with global leaders, Trivitron holds the record of 50,000+ installations across the globe. Today, Trivitron spearheads innovation in the fields of Newborn Screening, In-Vitro Diagnostics, Imaging & Radiology, Radiation Protection, Critical Care and Operating Room Solutions, thus, engraving its name as a holistic healthcare provider.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube.
